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Hospital, Paris, France, 14Pediatric Sleep Center, National Reference Network for Orphan Diseases (Narcolepsy and Idiopathic Hypersomnia),
Robert-Debre Hospital, Paris, France, 15Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern,
Switzerland, 16Department of Clinical Neurophysiology, University of Copenhagen, Glostrup, Denmark, 17Department of Psychiatry and
Psychotherapy, Sleep Disorders and Research Center, University Hospital Regensburg, Regensburg, Germany, 18Third Department of
Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland, 19Department of Neurology, Faculty of Medicine, Safarikiensis University
and Louis Pasteur Faculty Hospital Kosice, Kosice, Slovakia, 20Sleep Medicine, Barmelweid Clinic, Barmelweid, Switzerland and 21Department
of Neurology, University Hospital Zurich, Zurich, Switzerland
Keywords
age at onset, diagnostic delay, gender, genome-
wide association
Correspondence
Mehdi Tafti, PhD, Center for Integrative
Genomics (CIG), University of Lausanne, 1015
Lausanne, Switzerland.
Tel.: +4121 692 3971;
fax: +4121 692 3965;
e-mail: Mehdi.Tafti@unil.ch
*G.L. and J.H.-R. contributed equally to this
study.
†Other EU-NN members: Markku Partinen
(Finland), Brigit H€ogl (Austria), Karel Sonka
(Czech Republic), Luigi Ferini-Strambi (Italy)
and Renata Riha (UK).
Accepted in revised form 17 January 2013;
received 18 October 2012
SUMMARY
The aim of this study was to describe the clinical and PSG characteristics
of narcolepsy with cataplexy and their genetic predisposition by using the
retrospective patient database of the European Narcolepsy Network
(EU-NN). We have analysed retrospective data of 1099 patients with
narcolepsy diagnosed according to International Classification of Sleep
Disorders-2. Demographic and clinical characteristics, polysomnography
and multiple sleep latency test data, hypocretin-1 levels, and genome-
wide genotypes were available. We found a significantly lower age at
sleepiness onset (men versus women: 23.74  12.43 versus
21.49  11.83, P = 0.003) and longer diagnostic delay in women (men
versus women: 13.82  13.79 versus 15.62  14.94, P = 0.044). The
mean diagnostic delay was 14.63  14.31 years, and longer delay was
associated with higher body mass index. The best predictors of short
diagnostic delay were young age at diagnosis, cataplexy as the first
symptom and higher frequency of cataplexy attacks. The mean multiple
sleep latency negatively correlated with Epworth Sleepiness Scale (ESS)
and with the number of sleep-onset rapid eye movement periods
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DOI: 10.1111/jsr.12044 (SOREMPs), but none of the polysomnographic variables was
associated with subjective or objective measures of sleepiness. Variant
rs2859998 in UBXN2B gene showed a strong association (P = 1.28E-
07) with the age at onset of excessive daytime sleepiness, and
rs12425451 near the transcription factor TEAD4 (P = 1.97E-07) with
the age at onset of cataplexy. Altogether, our results indicate that the
diagnostic delay remains extremely long, age and gender substantially
affect symptoms, and that a genetic predisposition affects the age at
onset of symptoms.
INTRODUCTION
Narcolepsy with cataplexy (NC) affects ~20 per 100 000
individuals, with an incidence of ~0.3–0.6 per 100 000
person-years (Longstreth et al., 2007; Partinen and Hublin,
2011; Poli et al., 2013). Evidence indicates that NC is caused
by the loss of ~70 000 hypocretin cells in the hypothalamus,
and the best biological marker for human narcolepsy is the
reduction (or complete deficiency) of hypocretin-1 in the
cerebrospinal fluid (CSF; Nishino et al., 2000). NC displays a
strong genetic predisposition: more than 92% of Caucasian
patients (Mignot et al., 2001) carry the human leukocytes
antigen (HLA)–DQB1*06:02, while HLA–DQB1*06:03 allele
confers a strong protection (Hor et al., 2010). The tight
association with specific HLA alleles, the recent discovery of
circulating anti-TRIBBLES-2 antibodies (Cvetkovic-Lopes
et al., 2010), the potentially elevated antistreptolysin O titers
close to disease onset (Aran et al., 2009), the association
with a polymorphism of T-cell receptor alpha gene and a
polymorphism of the purinergic receptor P2RY11 gene
(Kornum et al., 2011) are strong indications of an autoim-
mune origin. However, the exact mechanism of such an
autoimmune process remains unknown.
Despite major advances in understanding the pathophysiol-
ogy of the disease and despite the fact that narcolepsy is a
serious chronic sleep disorder with a major impact on perfor-
mance, social relations, quality of life and socio-economic
burden (Jennum et al., 2012), many cases remain undiag-
nosed (Dodel et al., 2007; Ozaki et al., 2008; Vignatelli et al.,
2004). Variation in severity of the condition with incomplete or
atypical forms and variable symptoms might contribute to
under-diagnosis. Also, narcolepsy may be misdiagnosed as
another sleep disorder, psychiatric disorder, epilepsy or side-
effect of medication, or by lack of knowledge of the clinical
characteristics (Morrish et al., 2004). In addition, the exact
nosologyofnarcolepsy is still controversial for different reasons.
1. Narcolepsy with cataplexy can be diagnosed by history
alone (American Academy of Sleep Medicine, 2005) but
this approachmay not be accurate (Morrison et al., 2011),
as excessive daytime sleepiness (EDS) is a common
feature of many sleep disorders, and cataplexy has
common characteristics with experiences reported by
healthy subjects (Anic-Labat et al., 1999; Overeem et al.,
2011). Even if EDS in narcolepsy is different from that in
other sleep disorders, a precise description is missing in
the international criteria for NC. Nevertheless, significant
differences exist between the cataplexy-like episodes and
clear-cut cataplexy, such as the triggers and the muscles
involved (Anic-Labat et al., 1999; Sturzenegger and Bas-
setti, 2004). Additional symptoms, such as hypnagogic or
hypnopompic hallucinations (HH) and sleepparalysis (SP)
are frequent in the general population (Ohayon et al.,
1996, 1999; Sharpless and Barber, 2011).
2. Patients with NC may test negative in the proposed
multiple sleep latency test (MSLT) requirements. On the
other hand, patients with sleep apnea (Chervin and
Aldrich, 2000) and even normal subjects (Mignot et al.,
2006) may show short MSLT latencies and sleep-onset
rapid eye movement periods (SOREMPs). Even if the
prevalence of SOREMPs during MSLT in the general
population has not been exhaustively studied, some
evidence (Singh et al., 2006) suggests that 3.9% of the
general population can be positive for multiple SO-
REMPs. Aldrich underlined that 30% of patients in an
average sleep laboratory fulfilling both criteria, a mean
sleep latency <5 min and two or more SOREMPs, do not
have narcolepsy (Aldrich et al., 1997). With the more
recent limit of <8 min this percentage will even be greater.
3. From a clinical point of view, the spectrum of NC is still far
from being clearly delineated. The nosological limits
between narcolepsy without cataplexy (presenting with
all narcolepsy symptoms but cataplexy), with similar
polysomnographic (PSG) and MSLT abnormalities
(Dauvilliers et al., 2003; Mignot et al., 2002), idiopathic
hypersomnia without long sleep time, and non-organic
hypersomnia (Kaplan and Harvey, 2009) are in some
cases imprecise. There are many common clinical
aspects between narcolepsy without cataplexy and
idiopathic hypersomnia without long sleep time (note
also that the delay between EDS and cataplexy onset
may be highly variable), which may point to the need of
confirming proposed diagnostic criteria (Bassetti and
Aldrich, 1997; Bassetti et al., 2003; Billiard, 2007).
4. Although NC is tightly associated with HLA, genotype
can only support diagnosis, as the main susceptibility
allele (DQB1*06:02) is also found in about 25% of
healthy controls (Mignot et al., 2001).
5. Although NC is associated with low or undetectable
levels of hypocretin-1 in the CSF (normal hypocretin
levels in NC are exceptional; Knudsen et al., 2010), this
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measure is not routinely used in clinical practice. In
addition, low CSF hypocretin-1 levels were described in
other neurological or sleep disorders, such as in certain
cases of Guillain–Barre syndrome, anti-Ma encephalitis,
late stage of Parkinson’s disease, head trauma and in
Prader–Willi syndrome (Baumann et al., 2008; Fronczek
et al., 2009; Mignot et al., 2002; Overeem et al., 2004;
Ripley et al., 2001b).
6. Many studies emphasize the increased body mass index
(BMI) in patients with narcolepsy, as compared with
either idiopathic hypersomnia or the general population
(Kok et al., 2003; Poli et al., 2009), but the relationship
between the metabolic alterations and the duration of
untreated disease was not explored.
Given the preceding limitations, the aim of the present
study was to provide a reference detailed clinical and PSG
description of a large sample of patients with NC and their
eventual genetic predisposition. A major aim was to establish
the relationship between symptoms and the diagnostic delay.
To the best of our knowledge, our sample is the largest
population of well-defined NC ever reported.
PATIENTS AND METHODS
Patients were diagnosed in affiliated sleep centers of the
European Narcolepsy Network (EU-NN): France (n = 339);
the Netherlands (n = 219); Germany (n = 185); Spain
(n = 157); Italy (n = 68); Switzerland (n = 52); Denmark
(n = 41); Poland (n = 30); and Slovakia (n = 8), with a final
sample of 1099 patients. The data were gathered as a
retrospective EU-NN database during a European genome-
wide association study (GWAS; Hor et al., 2010) comparing
sporadic cases of narcolepsy with HLA-matched controls.
Patients were examined by physicians experienced with
narcolepsy, and the diagnosis was based on diagnostic
criteria of the ICSD-2 (American Academy of Sleep Medicine,
2005; Billiard, 2007). All patients had narcolepsy with
unambiguous clear-cut cataplexy, defined as sudden epi-
sodes of muscle weakness triggered by emotions. Given the
differences between sporadic and familial cases (e.g. the
frequency of HLA–DQB1*06:02 negative and CSF hypocre-
tin-1 normal cases; Mignot, 1998; Mignot et al., 2002),
suggesting a potential different pathogenesis (as demon-
strated in the canine model of narcolepsy; Ripley et al.,
2001a), only sporadic cases were included. All patients were
from European origin and were HLA–DQB1*06:02 positive.
The data were derived from a number of research projects,
some published (e.g. Dauvilliers et al., 2001; Hor et al.,
2010). Local ethics committees approved the recruitment of
patients for research protocols, and all patients gave their
consent to participate.
Patients were investigated in terms of the following.
1. Demographic characteristics: date of birth, gender,
height, weight, BMI at diagnosis. Circumstances at onset
(triggering factors) were not available in most patients.
2. Age at EDS onset and age at cataplexy onset. We
defined the age at onset of NC as the age at occurrence
of EDS and/or cataplexy, determined during the clinical
interview.
3. Frequency of cataplexy attacks at diagnosis. The fre-
quency of cataplexy was assessed by a scale from 1 to 5,
reporting rare to very frequent cataplexy attacks (Dauvil-
liers et al., 2001): 1 = one or less cataplexy attacks per
year; 2 = more than one cataplexy attack per year but
less than one per month; 3 = more than one attack per
month but less than one per week; 4 = more than one
per week but less than one per day; 5 = at least one
cataplexy attack per day.
4. Epworth Sleepiness Scale (ESS) score at diagnosis.
5. Polysomnographic variables [including apnea–hypopnea
index (AHI) and periodic leg movements during sleep
index (PLMSI) when available] and MSLT results (mean
sleep latency, number of SOREMPs) at diagnosis. Even
if the recording procedures were different amongst
centers, most of the patients underwent nocturnal in-lab
PSG followed by an MSLT as part of the diagnostic
evaluation. For PSG and MSLT, sleep latency was
defined as the time from lights off to the first epoch
scored as sleep. A SOREMP was defined as the
occurrence of an epoch of REM sleep within 15 min
after the first epoch scored as sleep. Although MSLT was
performed according to standard methods (Carskadon
et al., 1986), the number of scheduled naps could be
variable. To standardize the results, we calculated the
percentage of SOREMPs of the total number of naps:
percentage of naps with SOREMPs = [(number of
SOREMPs/number of MSLT sessions) 9 100].
6. Cerebrospinal fluid hypocretin-1 (measured by Phoenix
RIA kit) level when available.
7. Human leukocytes antigen–DQB1 genotyping was avail-
able from affiliated HLA or blood centers (at least 4 digits
typing by standard techniques).
8. Associated features, with particular attention to symp-
toms frequently reported with narcolepsy: SP; HH; and
poor nocturnal sleep.
9. Co-morbidities (sleep-related, somatic or psychiatric) and
treatment when available.
10. Genome-wide association study: to test genetic associ-
ations with clinical traits; age and gender were used as
covariates whenever they showed nominally significant
association with the tested trait (P < 0.05). Continuous
clinical phenotypes were inverse normal quantile trans-
formed before applying linear regression [including rele-
vant covariates and single nucleotide polymorphism
(SNP) imputed allele dosage]. For dichotomous clinical
traits logistic regression was used.
Statistical analysis
Descriptive analyses were performed for: gender; age at
diagnosis; age of symptom onset; symptoms at diagnosis;
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BMI, ESS, PSG and MSLT results; hypocretin-1 level;
frequency of co-morbidities and symptomatic treatments.
The interval between symptoms’ onset and diagnosis was
calculated. The gender effect on demographic (age at
symptoms’ onset, age at diagnosis, diagnostic delay, BMI)
and clinical variables (PSG, MSLT, sleepiness, frequency of
cataplexy and hypocretin level) was analysed using t-test/
Kruskal–Wallis/v2 test. Additional statistical analyses were
carried out using, when appropriate, t-test/ANOVA/Kruskal–
Wallis to test the effect of origin, BMI, sleepiness and
frequency of cataplexy. A possible interaction between BMI
and gender was evaluated by two-way ANOVA. Because not all
variables were available in all patients, the number of patients
in each test was different. To verify that the outcome of our
statistical tests was not affected by sub-sampling for each
variable, the effects of age and gender on BMI, diagnostic
delay and sleep characteristics were analysed by multivariate
regression analysis in a reduced sample with complete
information for variables of interest (n = 611). This analysis
did not reveal any major difference as compared with
analyses including the maximum number of patients for each
variable. Correlation coefficient (Pearson or Spearman) was
used to assess the relationship between demographic and
clinical variables. Statistical significance for all tests was
assumed when P < 0.05. For the entire sample and sepa-
rately, for each gender, we have performed principal com-
ponent analysis taking into account demographic, clinical,
PSG, MSLT and laboratory data. All statistical tests were




Data from 1099 patients were analysed. Table 1 shows
demographic characteristics of our sample. The changes in
sample size occurred because of missing data. Discrepan-
cies or absence of information in the charts were labeled as
data missing. For some data, manifestly outlier values were
removed [e.g. total sleep time (TST) <2 h, MSLT latency
>20 min, etc.].
In our sample, 54.8% of the patients were men and 45.2%
women. The birth distribution ranged from 1905 to 2004. No
predominance of any month or season was observed for
birth. The mean age at diagnosis was 36.9  17.1 years
(range: 4–87 years). The age of diagnosis varied depending
on the country of origin, with a mean age at diagnosis ranging
from 33.1  16.8 years in France to 43.9  17.6 years in
Spain (one-way ANOVA for factor ‘origin’, F = 9.234,
P < 0.001), but it was similar in women (36.9  16.9 years)
and men (36.8  17.4 years). Age at diagnosis and diag-
nostic delay were strongly correlated (r = 0.799, P < 0.001).
The strength of this correlation was maintained even after
excluding patients younger than 20 years old from the
analysis (r = 0.714, P < 0.001).
In most of the patients both EDS and cataplexy appeared
at the same time (48.8%), EDS preceded the onset of
cataplexy in 43.8% and cataplexy was the first reported
symptom in 7.4% of patients only. There were no significant
differences between countries or by gender. Based on clinical
interview, the age at EDS onset could be established in 990
patients. The mean age at EDS onset was 22.7 
11.9 years (range: 3–80 years; median: 20 years), with a
significant gender difference (t-test; Mann–Whitney
U = 107 302, P = 0.003; 23.7  12.4 years in men versus
21.5  11.8 years in women) but no difference between
countries. The mean age at cataplexy onset (n = 685) was
25.8  12.8 years (range: 5–80 years; median: 24 years),
with a normal distribution in both genders. The age of
cataplexy onset was significantly different between countries
(F = 3.088, P = 0.009; minimum in Italy, 23.0  12.1 years;
maximum in Germany, 32.9  11.3 years). In seven
patients, age at symptoms’ onset was older than 60 years
(EDS was the first symptom or appeared at the same time as
cataplexy). The mean delay between EDS onset and
cataplexy onset (n = 678) was 2.8  8.0 years. The maxi-
mum delay observed between EDS and cataplexy onset was
Table 1 Demographic characteristics of the sample
Parameter n (All) Mean  SD Men Women t/v2 P
Age at diagnosis (years) 755 36.87  17.13 36.80  17.40 36.91  16.86 NS NS
Age at EDS onset (years) 990 22.73  11.88 23.74  12.43 21.49  11.84 107 302 0.003*
Age at cataplexy onset (years) 685 25.80  12.84 26.05  13.25 25.45  12.25 NS
Diagnostic delay 738 14.63  14.31 13.82  13.79 15.62  14.94 60 950 0.044*
First symptom (%) NS
Cataplexy 47 7.40 8.10 6.50
Cataplexy and EDS 310 48.80 51.30 45.50
EDS 278 43.80 40.60 48.00
BMI 903 27.34  5.59 27.77  4.56 26.80  6.55 82 629 <0.001
Gender (% men) 590 54.80
*Mann–Whitney U, t-test for ranks; t: t-test; v2: Fisher’s exact test.
BMI, body mass index; EDS, excessive daytime sleepiness.
ª 2013 European Sleep Research Society
Narcolepsy phenotypes 485
48 years, and the maximum delay between cataplexy onset
and EDS was 40 years.
Available data from 738 patients revealed that the mean
delay between the onset of the first clinical symptom (EDS or
cataplexy) and diagnosis was 14.6  14.3 years (median
10.5 years; range from <1 to 67 years). The delay between
disease onset and diagnosis was larger for patients with later
age at onset, and for those with EDS as first symptom
(r = 0.169, P < 0.001). An important variability between
countries was observed for diagnostic delay (F = 8.042,
P < 0.001), with the lowest delay in France (11.9 
13.7 years) and the highest one in Spain (21.1  14.7 years).
Nevertheless, diagnostic delay was influenced by the time of
diagnosis (for the analysis of the time of diagnosis, groups
were created by 10-year intervals). For all countries, cases
diagnosed before 1991 have a significantly decreased delay
(mean diagnostic delay before 1991 was 8.0  4.7 years,
compared with the ones diagnosed after). One explanation
could be the accumulation in time of undiagnosed cases. The
higher number of cases diagnosed before 1991was in France,
while in Spain the increase in number of cases was observed
starting with 1991. For the entire sample, the best predictors of
diagnostic delay (forward stepwise regression) were age at
diagnosis, first symptom and the frequency of cataplexy
(Table 2).
Clinical and laboratory data
BMI
The mean BMI at diagnosis (n = 903) was 27.3 
5.6 kg m2. About two-thirds of the patients were overweight
or obese (36.5% had a BMI between 25 and 29.9 kg m2,
and 27.2% a BMI > 30 kg m2). In patients with a normal
weight range (BMI < 25 kg m2) there was a predominance
of women (men versus women: 41.8% versus 58.2%,
v2 = 40.867, P < 0.001), for overweight patients a predom-
inance of men was observed (BMI between 25 and
29.9 kg m2, men versus women: 66.7% versus 33.3%;
BMI > 30 kg m2, men versus women: 54.5% versus 45.5%;
v2 = 21.023, P < 0.001). Patients with a normal BMI had a
lower age at diagnosis, age of first symptom onset and
diagnostic delay. To control for gender by BMI interaction, the
age at diagnosis, age at symptom onset and diagnostic delay
were also analysed by two-way ANOVA. Results indicated that
gender and BMI affected all three variables, but none was
affected by gender by BMI interaction (P > 0.3 for all
comparisons). We also observed significant differences in
PSG data [TST, sleep efficiency (SE), slow-wave sleep
(SWS) and REM sleep duration are reduced, and S1 duration
is increased in overweight and obese patients most probably
due to an increase in sleep apnea severity; Table 3].
Nevertheless, none of the variables that assess the severity
of sleepiness (the mean sleep latency during MSLT, number
of SOREMPs, ESS), or frequency of cataplexy and hypocre-
tin-1 levels, was different between patients with normal BMI
versus overweight/obese.
Subjective sleepiness
Subjective sleepiness was assessed using the ESS in 803
patients at the time of diagnosis. The mean ESS was
17.4  3.9 with a median score at 18. Only 38 patients
(4.7%) had an ESS in the ‘normal ranges’ (<11). None of the
‘non-sleepy’ patients was under stimulant medication at
diagnosis. The mean age at diagnosis in this group was not
different from that of the group with ESS score > 10
(31.6  14.9 years versus 37.3  17.4 years), but the diag-
nostic delay was shorter (7.8  7.0 years versus
14.7  14.6 years, P = 0.011; Table 4). The first symptom
in ‘non-sleepy’ patients was cataplexy in 12%, higher than in
those who declared themselves sleepy (7.2%), but the
difference was not statistically significant. The variables
correlated with sleepiness were different between these two
groups of patients, but the severity of narcolepsy symptoms
was similar. The number of SOREMPs was significantly
higher in patients with high ESS scores (67.94% in high ESS
versus 17.32% in normal ESS, t = 15.33, P < 0.0001).
Cataplexy
The frequency of cataplexy was assessed on a scale from 1
to 5, from rare to very frequent cataplexy attacks. In our case
series (n = 829), almost two-thirds of the patients had
frequent or very frequent cataplexy attacks (scores 4 + 5:
62.6%; score 5: 41.9%), and 48 patients (5.8%) had very rare
cataplexy attacks. The mean frequency of cataplexy score
was 3.7  1.3, which corresponds to more than one attack
per month. Patients with severe cataplexy (score 5) had a
reduced diagnostic delay (11.9  12.8 years versus
18.3  15.8 years, P < 0.001), and the percentage of those
who experienced sleepiness, HH and SP was higher in
patients with severe cataplexy (Table 5).
Associated features
Hypnagogic or hypnopompic hallucinations were experi-
enced by 63.1% of patients (370 patients), and 52.6% (257
patients) experienced SP; both symptoms were present in
43.6% (175 patients). Only 28.2% (303 patients) of the
entire patient population reported either SP or HHs alone
(Table 6).
Table 2 Forward stepwise regression for best predictors of
diagnostic delay
Step no. Vars. entered r R2 P
1 Age at diagnosis 0.714 0.509 0.006
2 First symptom 0.732 0.536 <0.001
3 Cataplexy frequency 0.738 0.545 <0.001
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PSG features
Table 7 shows PSG and MSLT characteristics of patients
with NC. The mean TST was 411.7  80.4 min, with a mean
SE of 83.8  11.5%; 42.8% had abnormal SE < 85%. The
age at diagnosis was negatively correlated with TST
(r = 0.389, P < 0.001), SE (r = 0.335, P < 0.001), SWS
duration (r = 0.293, P < 0.001) and REM sleep duration
(r = 0.209, P < 0.001), and positively with S1 duration
(r = 0.315, P < 0.001). The mean number of stage shifts was
108.3  64.6, and the mean wake after sleep onset was
59.5  43 min. The mean sleep-onset latency (SOL) was
Table 3 Demographic, clinical and PSG characteristics of the patients, according to BMI
Parameter n BMI < 25 kg m2 BMI 25–29.9 kg m2 BMI > 30 kg m2 F/K–W P
Age at diagnosis (years) 699 30.54  15.12 42.30  17.41 39.57  17.04 35.77 <0.001
Age at EDS onset (years) 878 19.94  10.29 25.38  12.85 23.62  12.10 17.66 <0.001
Age at cataplexy onset (years) 642 22.78  11.87 29.52  13.76 25.74  12.30 16.924 <0.001
Diagnostic delay 686 11.02  12.07 16.70  15.40 17.45  15.58 14.547 <0.001
First symptom (%) 597
Cataplexy 6.70 8.70 6.50 1.003 0.606
Cataplexy and EDS 47.30 46.30 53.50
EDS 46.00 45.00 40.00
Gender (% men) 41.80 66.70 54.50 3.536 <0.001
HH (% positive) 65.80 62.50 59.00 2.396 0.302
SP (% positive) 54.80 55.30 50.20 1.501 0.472
HH and SP (% positive) 45.70 45.00 41.30 2.519 0.281
EDS, HH and SP (% positive) 44.40 42.00 38.30 3.041 0.219
ESS score 17.16  3.91 17.63  3.83 17.58  3.91 1.209 0.3
EDS (% positive) 95.10 95.60 95.00 0.094 0.954
Frequency of cataplexy (%)
1 (one or less cataplexy
attacks per year)
4.70 8.90 3.70 2.201 0.333
2 (more than one cataplexy
attacks per year, but less
than one per month)
13.40 11.70 14.30
3 (more than one attack per
month, but less than one
attack per week)
18.10 20.60 16.40
4 (more than one attack per
week, but less than one
per day)
22.00 17.50 19.00
5 (at least one cataplexy
attack per day)
41.90 41.20 46.60
Sleep latency in PSG
TST 686 427.22  69.70 407.38  82.69 392  80.59 22.969 <0.001
SE 761 86.51  16.99 82.59  11.90 81.76  12.04 35.857 <0.001
Stage1 (% of TST) 722 12.16  8.76 15.26  10.65 16.72  10.72 27.248 <0.001
Stage 2 (% of TST) 721 43.56  11.27 44.26  12.78 42.82  12.56 1.601 0.449
SWS (% of TST) 753 19.50  9.53 15.97  10.00 17.20  8.53 21.792 <0.001
REM (% of TST) 733 20.26  7.51 19.41  8.34 17.21  8.53 14.281 0.001
REM SOL 743 47.03  55.51 59.24  64.23 52.42  65.50 2.316 0.314
SOL 752 9.97  15.20 10.57  30.82 8.61  13.61 2.906 0.234
Mean sleep latency at MSLT 816 3.98  3.06 3.78  3.06 3.79  2.70 1.164 0.559
Number of SOREMP (%) 777
0–15 4.40 4.40 3.90 0.382 0.826
20–40 21.10 21.60 18.60
50–75 29.60 32.40 36.10
80–100 44.90 41.80 41.40
Hypocretin (%)
0–40 pg mL1 80.20 89.80 90.10 5.186 0.75
>40 pg mL1 19.80 10.20 9.90
F-value: derived from one-way ANOVA.
BMI, body mass index; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or hypnopompic hallucination;
K–W, Kruskal–Wallis test for not normally distributed variables; MSLT, multiple sleep latency test; PSG, polysomnography; REM, rapid eye
movement; SE, sleep efficiency; SOL, sleep-onset latency; SOREMP, sleep-onset REM period; SP, sleep paralysis; SWS, slow-wave sleep;
TST, total sleep time.
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Table 4 Significant differences due to sleepiness (EDS: upper, MSLT: lower table)
Variable n ESS 0–10 ESS > 10 t P
Diagnostic delay 627 7.81  7.04 14.7  14.6 6.488 0.011
SE 691 87.06  11.2 83.47  11.17 5.491 0.019
Mean sleep latency on MSLT 774 5.99  3.94 3.75  2.9 15.307 <0.001
Number of SOREMP (%) 803




Variable n MSLT  8 MSLT > 8 v2/t P
Age at EDS onset (years) 870 23.36  12.14 19.8  11.03 6.727 0.009
Age at cataplexy onset (years) 623 26.33  12.93 21.94  11.55 5.305 0.021
ESS 774 17.73  3.69 14.95  4.26 30.978 <0.001
Number of SOREMP (%) 788




EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; MSLT, multiple sleep latency test; SE, sleep efficiency; SOREMP,
sleep-onset rapid eye movement period.
Table 5 Significant differences due to the severity of cataplexy
Variable/frequency
of cataplexy 1 2 3 4 5 F/K–W P
Diagnostic delay 16.67  14.76 18.30  15.84 15.11  14.29 14.88  14.59 11.91  12.82 4.480 0.001
EDS, HH and SP
(% positive)
17.50 28.70 42.50 40.60 51.40 10.125 <0.001
F-value: derived from one-way ANOVA.
EDS, excessive daytime sleepiness; HH, hypnagogic or hypnopompic hallucination; K–W, Kruskal–Wallis test for not normally distributed
variables; SP, sleep paralysis.
Table 6 Clinical variables
Parameter n (all) Mean  SD Men Women t-test P
HH (% positive) 587 63.10 58.90 68.00 8.030 0.005
SP (% positive) 488 52.60 50.20 55.50 NS
HH and SP (% positive) 402 43.60 40.40 47.60 6.622 0.01
EDS, HH and SP (% positive) 301 41.80 38.90 44.60 NS
ESS score 803 17.45  3.86 17.33  3.91 17.57  3.80 NS
EDS (% positive) 765 95.30 95.40 95.10 4.488 0.034
Frequency of cataplexy (%)
1 (one or less cataplexy attacks per year) 48 5.80 6.80 4.60 NS
2 (more than one cataplexy attacks per
year, but less than one per month)
108 13.00 11.40 15.30
3 (more than one attacks per month,
but less than one attack per week)
154 18.60 18.60 18.50
4 (more than one attack per week, but
less than one per day)
172 20.70 19.20 22.60
5 (at least one cataplexy attack per day) 347 41.90 44.10 39.00
EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or hypnopompic hallucination; SP, sleep paralysis.
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10.3  23.8 min, with a mean REM sleep latency (REM SL)
of 54.6  65.30 min. Thirty-five percent of patients had a
SOREMP during the night PSG (REM SL < 15 min), and
only 14.2% had a REM SL between 90 and 150 min, with
some patients showing prolonged REM latency (REM
SL > 150 min; 9.1%). The distribution of REM SL was
bimodal, with a first peak between 0 and 10 min after sleep
onset, and a second less marked peak at 50–70 min.
Women had a better SE, longer S2 and SWS duration, and
shorter S1.
To evaluate whether the ESS and/or MSLT results are
influenced by night sleep, a multiple regression analysis was
performed, controlling for age at diagnosis and gender. None
of the variables was retained in the analysis, suggesting that
changes in sleep structure or duration are due to age and
gender, but not to the condition.
The mean sleep latency during MSLT in 927 patients
(without treatment) was 3.9  3.0 min, with a median at
3 min, indicating severe sleepiness; 92% of the patients had
a sleep latency < 8 min (Table 7). Although small, the mean
sleep latency at MSLT was significantly shorter in women
(3.68  2.7 min versus 4.10  3.24 min in men). The mean
percentage of SOREMPs during the MSLT was
65.9  27.2%, which corresponds roughly to 3 SOREMPs
during a 5-naps MSLT. However, 3.9% of the sample had no
SOREMPs during the MSLT, and an additional 5.7% had
20% SOREMPs, which corresponds to 1 SOREMP during a
5-naps MSLT. Laboratory criteria currently used to diagnose
narcolepsy (sleep latency shorter than 8 min and at least 2
SOREMPs) were present in 90.3% of patients. We found a
negative correlation between the mean sleep latency at the
MSLT and the number of SOREMPs (r = 0.326,
P < 0.001). Reduced MSLT mean sleep latency predicted
SOREMPs (r = 0.326, P < 0.001). The MSLT latency was
negatively correlated with the ESS (r = 0.306, P < 0.001).
CSF hypocretin-1
Cerebrospinal fluid hypocretin-1 measurements were avail-
able in 294 patients (Table 7). In 96.3% of the patients
hypocretin-1 levels were undetectable (<40 pg mL1,
n = 252) or <110 pg mL1 (n = 31). In the remaining 11
patients, intermediate (four cases) to normal levels (seven
cases) were obtained (from 118 to 400 pg mL1). There
were no significant correlations between hypocretin-1 levels
(analysed as bivariate parameter: <40 pg/ml and more than
40 pg/ml) and variables of interest; there were no differences
in clinical features between patients with undetectable and
those with hypocretin-1 levels between 40 and 110 pg mL1.
Regarding the 11 patients with intermediate to normal values
of hypocretin-1, the only significant difference was observed
in the frequency of cataplexy, which was lower (frequency
code 1–2: 42.9% versus 11% in patients with low/undetect-
able levels of hypocretin-1, P = 0.004).
Effect of age and gender on NC features and diagnostic
delay
Diagnosis is more delayed in women of all age groups (two-
way ANOVA for ‘age group’ and ‘gender’, P < 0.001; no
interaction; men versus women: 13.8  13.8 years versus
15.6  14.9 years), independently from the origin or the time
at diagnosis. Stage 1 was increased in men in all age groups
(men versus women 16.5  10.9% versus 13.0  9.2%;
Mann–Whitney U: 55949, P < 0.001). Younger men were
sleepier than younger women (ESS in men 20–30 years old
Table 7 PSG and MSLT variables and hypocretin-1 levels
Parameter n (all) All mean  SD Men Women t-test P
TST 751 411.70  80.45 410.33  79.85 414.26  80.38 NS
SE 848 83.80  11.53 82.86  11.20 84.95  11.82 74 791 <0.001*
Stage 1 (% of TST) 772 14.62  10.36 16.46  10.89 12.96  9.21 55949.9 <0.001*
Stage 2 (% of TST) 773 43.75  12.3 43.04  12.55 44.74  11.91 66203.5 0.03*
SWS (% of TST) 808 17.54 9.97 16.36  9.88 18.86  9.89 67725.5 <0.001*
REM (% of TST) 788 19.17 8.54 19.27  8.16 19.04  8.98 NS
REM-onset latency 835 54.59  65.30 55.03  67.39 53.92  62.91 NS
SOL (PSG) 844 10.33  23.80 11.86  28.35 9.30  14.75 NS
Mean sleep latency (MSLT) 927 3.92  3.03 4.10  3.23 3.67  2.70 NS
Number of SOREMP (%)
0–15 34 4.00 3.80 4.30 NS
20–40 169 20.50 22.90 17.70
50–75 265 32.10 27.90 36.80
80–100 358 43.40 45.30 41.30
Hypocretin (%)
Undetectable (<40 pg mL1) 254 86.40 55.11 44.89
(>40 pg mL1) 40 13.60 57.50 42.50
*Mann–Whitney U-test, t-test for ranks.
MSLT, multiple sleep latency test; PSG, polysomnography; REM rapid eye movement; SE, sleep efficiency; SOL, sleep-onset latency;
SOREMP, sleep-onset REM period; SWS, slow-wave sleep; TST, total sleep time.
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versus women 17.4  3.8 versus 16.8  3.9, P = 0.04), but
with aging women declared themselves sleepier (ESS in men
>60 years old versus women 17.6  3.8 versus 18.8  3.8,
P = 0.034). The same pattern was observed in parameters
correlated with sleepiness: mean SOL during MSLT (young
men versus young women 3.7  2.7 min versus
4.04  2.6 min, P = 0.04; men > 60 years old versus
women 4.1  3.6 versus 3.9  2.8, P = 0.53) and SO-
REMPs (young men versus young women 67.3  28.1
versus 63  29; men > 60 years old versus women
59.0  26.2 versus 70.8  25.0, P = 0.014).
Principal component analysis
For variables relevant from a clinical point of view we
performed a principal component analysis, varimax rotation
with Kaiser normalization (KMO measure of sample ade-
quacy 0.611; Bartlett’s test of sphericity: chi square 1010.20;
P < 0.001). This analysis was performed for the entire
sample and, separately, for each gender. Table 8 presents
the major extracted components (eigenvalue > 1; no restric-
tion on selected number of components). For the entire
sample, eight components accounted for 67.05% of pheno-
type variability. By gender analysis retrieved only seven
components for each gender.
For the entire sample, the first major component (%
variance explained = 14.33%) included age- and PSG-
related variables: age at diagnosis; diagnostic delay and
non-REM sleep stage 1 (positively); TST and SE (negatively;
Table 8). The second component (% variance
explained = 12.68%) accounted for sleepiness, with ESS
score, presence of EDS, and number of SOREMPs during
MSLT (positively) and mean MSLT (negatively). Components
three and four (% variance explained = 7.7% and 7.6%,
respectively) were represented by sleep variables. The
frequency of cataplexy was extracted (positively) together
with the presence of sleepiness, HHs and SP as part of
component five (% variance explained = 7.1%). First symp-
tom, diagnostic delay and BMI, SOL, and CSF hypocretin-1
levels with stage 1 (positively) and mean MSLT (negatively)
were extracted separately within components 6–8. By gender
analysis revealed effects that could not be assessed by other
analysis. Compared with the entire sample, the most impor-
tant variability in men was due to sleepiness and its
correlates. In men, diagnostic delay was influenced by the
severity of cataplexy and the first symptom (if cataplexy was
the first symptom, the diagnostic delay was shorter). In
women, those who had cataplexy as the first symptom had a
lower REM-onset latency.
Other sleep-related disorders
Respiratory parameters were not systematically assessed in
most sleep laboratories when evaluating a patient suspected
Table 8 Principal component analysis
Rotated component matrix
Component
1 2 3 4 5 6 7 8
BMI 0.312 0.073 0.306 0.039 0.191 0.314 0.210 0.023
Age at diagnostic 0.776 0.109 0.089 0.150 0.195 0.157 0.142 0.074
Diagnostic delay 0.730 0.112 0.102 0.058 0.198 0.331 0.134 0.199
Frequency of cataplexy 0.027 0.039 0.069 0.053 0.733 0.158 0.008 0.062
TST 0.749 0.015 0.076 0.086 0.148 0.145 0.153 0.022
SE 0.737 0.011 0.048 0.012 0.124 0.183 0.189 0.028
Stage 1 0.442 0.045 0.460 0.203 0.014 0.174 0.248 0.429
Stage 2 0.178 0.057 0.103 0.869 0.095 0.124 0.120 0.226
SWS 0.279 0.093 0.056 0.754 0.062 0.136 0.137 0.290
REM 0.165 0.038 0.733 0.178 0.032 0.040 0.047 0.028
SOL 0.089 0.008 0.085 0.007 0.041 0.047 0.875 0.094
REM latency 0.002 0.011 0.731 0.031 0.051 0.184 0.246 0.173
Mean MSLT 0.061 0.506 0.031 0.039 0.193 0.120 0.043 0.330
No. SOREMPs 0.027 0.871 0.026 0.007 0.037 0.014 0.031 0.057
ESS score 0.098 0.885 0.049 0.029 0.049 0.073 0.054 0.021
EDS 0.107 0.693 0.025 0.031 0.245 0.041 0.069 0.094
Hypocretin 0.138 0.116 0.125 0.034 0.090 0.228 0.135 0.738
EDS + HH + SP 0.002 0.261 0.024 0.026 0.730 0.150 0.044 0.013
First symptom 0.005 0.038 0.080 0.010 0.047 0.811 0.057 0.137
BMI, body mass index; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or hypnopompic hallucination;
MSLT, multiple sleep latency test; REM, rapid eye movement; SE, sleep efficiency; SOL, sleep-onset latency; SOREMP, sleep-onset REM
period; SP, sleep paralysis; SWS, slow-wave sleep; TST, total sleep time.
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of NC. In 240 patients detailed breathing parameters were
available. The mean AHI was 5.1  10.6 per hour, with
26.3% having an AHI  5 per hour, 8.7% an AHI between 5
and 15 per hour, and 4.1% an AHI  15 per hour. The AHI
was higher in men than in women (7.63  13.3 versus
3.3  6.7, P = 0.007), and correlated with BMI (r = 0.208,
P = 0.002). No significant correlation was found with sleep-
iness (MSLT latency: r = 0.012, P = 0.86; ESS: r = 0.36,
P = 0.617). Patients with AHI > 30 per hour tended to be
older than those with AHI <30 per hour (40.5  23 versus
35.3  17.2, P = 0.22), and had higher BMI (30.6  5.6
versus 27  5.4, P = 0.043).
The PLMSI was available in 174 patients only. The mean
PLMSI was 1.5  25.8 per hour of sleep, with a median at
4.6 per hour; 49.4% had a PLMI > 5 per hour and 30.4% a
PLMI > 15 per hour.
In a subgroup of 295 patients, the presence of REM sleep
behavior disorder (RBD; confirmed during diagnostic PSG or
clinically suspected) was established in 46% of men and 54%
of women. No differences between patients with NC with and
without RBD were found for sex distribution, age at diagnosis,
ESS score or mean latency during MSLT.
Two-hundred and seventy patients were evaluated for
other parasomnias than RBD. The most frequent parasom-
nias were: sleep talking (17%); arousal disorders (confu-
sional arousals, sleepwalking, sleep terrors, in 8.1%); and
bruxism (5.9%). Four patients (1.4%) exhibited characteris-
tics of sleep-related eating disorders: one associated with
arousal disorders, another associated with sleep talking, and
two without other associated parasomnias.
Genome-wide association
To verify if any gene variant may be associated with
narcolepsy phenotypes, we performed a GWAS in 585
patients who had been genotyped as part of a case–control
GWAS recently published (Hor et al., 2010). Among
potential associations, 13 top hits were genotyped in 387
additional narcolepsy patients for replication. Table 9 shows
the associations between the top 13 hits for the original, the
replication and the whole sample metanalysed. None of the
selected variants reached a genome-wide significance level
(P < 5E-08). Nevertheless, a SNP (rs2859998) within the
UBXN2B, an adaptor protein required for Golgi and endo-
plasmic reticulum biogenesis, was strongly associated
(metanalysis P = 1.28E-07) with the age at onset of EDS.
A similar strong association was also found between
rs12425451 near the transcription factor TEAD4 and the
age at onset of cataplexy (metanalysis P = 1.97E-07). The
later association was the only significant one in the
replication sample (P = 0.048), suggesting a potential true
signal that needs further replication in other independent
samples.
DISCUSSION
In this study we were able to analyse phenotypic and genetic
data of 1099 sporadic HLA–DQB1*06:02 positive patients
with NC from the retrospective database of the EU-NN
connecting sleep laboratories from France, the Netherlands,
Germany, Spain, Italy, Denmark, Switzerland, Poland, Slo-
Table 9 Genome-wide association analysis of narcolepsy phenotypes
Phenotype rs# aA aB x1 p1 x2 p2 x_meta p_meta
ESS (n1 = 418, n2 = 252) rs16966122 A G 2.3655 9.11E-07 0.8656 6.82E-02 1.601 2.08E-06
Age EDS onset (n1 = 530,
n2 = 319)
rs2859998 A G 4.6048 2.33E-07 3.0064 2.20E-01 4.4145 1.28E-07
Age EDS onset (n1 = 530,
n2 = 319)
rs6072697 C T 14.8434 4.29E-06 4.4731 2.76E-01 10.8306 1.84E-05
Age cataplexy onset (n1 =
435, n2 = 305)
rs12425451 C T 7.9529 7.30E-07 4.5204 4.83E-02 6.7866 1.97E-07
HH (n1 = 458, n2 = 310) rs10160605 A G 0.8865 3.84E-06 0.0294 8.48E-01 0.363 2.43E-03
TST (n1 = 442, n2 = 180) rs304468 C T 28.7108 1.18E-06 9.1773 2.65E-01 15.7748 1.00E-03
TST (n1 = 442, n2 = 180) rs890227 A G 149.2937 4.11E-07 16.656 3.77E-01 31.3251 4.82E-02
SE (n1 = 451, n2 = 268) rs1515773 C T 5.6438 3.37E-07 3.083 1.80E-01 3.9944 6.10E-05
SE (n1 = 451, n2 = 268) rs2426087 A G 11.638 4.30E-07 1.9517 7.94E-01 10.463 1.98E-06
SOREMPs (n1 = 490,
n2 = 298)
rs9397716 C T 11.7672 2.13E-05 0.0022 9.40E-01 0.0009 9.75E-01
SOREMPs (n1 = 490,
n2 = 298)
rs9551427 A G 10.883 2.28E-05 0.0345 1.32E-01 0.0336 1.41E-01
BMI (n1 = 463, n2 = 307) rs1882687 A C 2.1251 3.90E-07 0.3574 4.95E-01 1.1544 4.13E-04
REMS (n1 = 429, n2 = 260) rs17294110 A G 3.0476 8.91E-06 2.5829 8.55E-02 2.0692 9.07E-04
rs#: SNP; aA and aB: minor and major alleles; x1 and x2: effect size for discovery and replication; meta: metanalysis; n1 and n2: number of
patients in discovery and replication analyses.
BMI, body mass index; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or hypnopompic hallucination;
REMS rapid eye movement sleep; SE, sleep efficiency; SOREMP, sleep-onset REM period; TST, total sleep time.
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vakia, Czech Republic, Austria, Finland and UK. This is, to
our knowledge, the largest published population of well-
defined NC. We used this large sample of patients to further
describe the clinical picture and the PSG characteristics of
NC, to review the major features of NC, and genetic
association with all available phenotypes. Below we will
discuss the major findings.
Diagnostic phenotypes
Although NC can be clinically diagnosed by the presence of
EDS and cataplexy, this is still not accurate enough in many
cases, in particular in incomplete and atypical forms, or in
patients with co-morbidities such as sleep apnea. In addition,
EDS is common in other sleep disorders, and cataplexy,
especially incomplete attacks, is not always easy to identify.
For these reasons several other phenotypic criteria are
widely used to support the diagnosis. Among these, HLA,
hypocretin-1 and MSLT criteria are the most widely accepted
ones. In our population, all cases had documented cataplexy
and were HLA–DQB1*06:02 positive, allowing us to evaluate
the contribution of other phenotypic variables. Although
available in only 294 patients (but still the largest sample
ever reported), normal hypocretin-1 levels were found in only
seven patients (2.38%), indicating, as reported by others,
that hypocretin deficiency is the most reliable and sensitive
biological marker for NC, even if not practically performed in
everyday clinical practice. Among 927 patients with MSLT,
74 (8%) had a mean MSLT > 8 min and 79 (8.5%) had <2
SOREMPs, suggesting that MSLT criteria have a lower
diagnostic value. Using the criteria proposed by Poli et al.
(2013) (EDS and unambiguous cataplexy and MSLT mean
sleep latency  8 min or MSLT SOREMPs  2), 96.9% of
the patients met the criteria. Nevertheless, among 79 with
< 2 SOREMPs, 41 (53%) had a SOREMP during the
preceding night PSG. Adding the PSG SOREMPs to those
with 1 SOREMP during MSLT brings the percentage of
patients with SOREMPs > 2 up to 94.1%, suggesting a good
diagnostic value that can be routinely used, as recently
suggested (Andlauer et al., 2012). Interestingly, among
seven hypocretin-1 normal patients, MSLT data were avail-
able in three, and all three had mean MSLT <8 min with
more than 2 SOREMPs. The same observation was found in
two out of the four patients with intermediate hypocretin-1
levels. Overall, EDS, cataplexy and DQB1*06:02 best
characterize the condition, in the absence of hypocretin-1
measure. MSLT data together with PSG SOREMPs remain
highly valuable, especially if the HLA typing is not available.
Also note that in our population mean MSLT negatively
correlated with the ESS score (r = 0.302, P < 0.001).
Accordingly, principal component analysis identified ESS,
mean MSLT and number of SOREMPs contributing to the
same factor with strong correlations between them. In other
disorders with EDS as the leading symptom this correlation
cannot be demonstrated (Chervin and Aldrich, 1999; Shpirer
et al., 2006).
Time between narcolepsy onset and diagnosis
The delay between the first symptom and diagnosis has been
previously reported to range from the same year to more than
60 years (Morrish et al., 2004; Parkes et al., 1995), usually
more than a decade, with a mean delay between 15 and
17 years after the onset of EDS (Moldofsky et al., 2000;
Morrish et al., 2004). Although it is generally claimed that the
diagnostic delay has considerably shortened in recent years,
in our population the mean diagnostic delay is still substantial
(14.6  14.3 years). Interestingly, patients with older age at
onset had longer diagnostic delay, while younger patients
(mainly children and adolescents) have the shortest diag-
nostic delay. Also, patients with EDS as the first symptom
have longer diagnostic delay as compared with those with
both EDS and cataplexy or cataplexy as the first symptom.
Age at symptom onset and age at diagnosis varied amongst
countries. Obviously several factors might be involved,
including but not limited to differences in the recruitment
population (child versus adult patients) and history of narco-
lepsy research in each country. Another interesting finding is
the significant between-country differences in diagnostic
delay, with the shortest in France (11.9  13.7 years) and
the longest in Spain (21.1  14.7 years). Nevertheless, the
diagnostic delay also depended on the year of diagnosis, with
those diagnosed before 1991 having the shortest delay
(8.0  4.7 years). This paradoxical finding can be explained
by a sharp increase in awareness and the number of
narcolepsy specialists in the 1980s. In summary, the best
predictors of a short diagnostic delay are the young age at
diagnosis, the first symptom including cataplexy, and the
higher frequency of cataplexy. These observations are in
accordance with previous reports indicating that the year of
symptom onset and whether or not cataplexy is one of the
initial symptoms show a significant correlation with the
diagnosis delay (Morrish et al., 2004). Overall, the onset or
worsening of cataplexy often prompts patients to look for
medical assistance (Rye et al., 1998), the interval between
symptom onset and diagnosis is greater in patients whose
symptom onset was further in the past (Dauvilliers et al.,
1998), and a reduction in the diagnosis delay is found in
patients with a more recent date of birth (Furuta et al., 2001).
Age and gender contributions
Gender differences in narcolepsy phenotypes are poorly
investigated. Here we found a significantly longer diagnostic
delay in women. Also, the age at onset for EDS was lower in
women. These differences seem robust as there were no
gender differences between countries or the time of diagno-
sis, while the age at onset for cataplexy was highly
significantly different between countries. Mean sleep latency
at MSLT was significantly shorter in women, in addition to
several PSG and BMI differences. Our findings clearly
indicate that narcolepsy symptoms are strongly affected by
age and especially gender, needing further investigations.
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Multivariate analysis
Using the most typical phenotypes in our multivariate
analysis, we identified up to eight factors explaining their
variance in a large NC population. As expected, the most
significant one included age at diagnosis and diagnostic
delay negatively correlated with TST and SE, and positively
with the amount of stage 1 non-REM sleep. The second most
significant component includes variables related to EDS, with
ESS score and number of SOREMPs during MSLT being
negatively correlated with mean sleep latency during MSLT.
BMI segregated positively with stage 1 non-REM sleep and
REM latency at night, and negatively with diagnostic delay
and nocturnal REM sleep. Of interest, the levels of hypocre-
tin-1 positively correlated with stage 1 non-REM sleep and
negatively with mean latency during MSLT. Note that none of
the night PSG variables was associated with subjective
(ESS) or objective measures of sleepiness (MSLT), suggest-
ing that EDS in narcolepsy does not result from poor quality
night sleep, as already proposed (Broughton et al., 1994).
Overall, our analysis successfully identified groups of corre-
lated symptoms, each explaining between 5.8 and 14.33% of
phenotypic variance (total variance explained by eight
factors = 67%).
Genetics of narcolepsy phenotype
We performed the first GWAS on narcolepsy clinical and
laboratory phenotypes. Although many suggestive variants
were found, only one, associated with the age at onset of
cataplexy, showed a nominal significant association in the
replication sample. The major explanation for this negative
result is the complexity of the analysed phenotypes where
genetic variants explain a small proportion of the phenotypic
variance. Also, our original sample (585 patients) is somehow
too small to have enough power to detect a genome-wide
significant signal (note also that data for different phenotypes
were not available in all 585 patients further reducing the
statistical power). Nevertheless, the variant rs12425451
associated with the age at onset of cataplexy is in the vicinity
of the transcription factor TEAD4. TEAD4 is an important
transcription factor controlling neuronal fate and survival (Cao
et al., 2008). This interesting finding needs replication.
CONCLUSION
In this large sample of well-defined patients with NC, our
findings are compatible with previously published studies,
extending data collected in smaller case-series. In addition
we have identified several unexplored relationships between
narcolepsy phenotypes. The long delay between the onset of
symptoms and diagnosis implies that many cases still remain
undiagnosed, and that major efforts need to be made to
spread the knowledge of the disease among the population
and in particular among physicians. Note that longer diag-
nostic delay is found here associated with higher BMI,
suggesting that late diagnosis and/or undiagnosed cases are
at higher risk for metabolic and cardiovascular diseases. Our
findings also emphasize a large heterogeneity in the clinical
presentation and laboratory variables of the disease, and
point out the fact that accurate diagnosis needs to take into
account the full clinical presentation and a critical interpre-
tation of PSG and MSLT results. Although not routinely
proposed, the measurement of hypocretin-1 concentration in
the CSF could be an important diagnostic tool in dubious
cases. Future studies should also take into account the
gender as a major contributor.
Finally, we acknowledge several limitations of our study.
Although the diagnosis was made in reference sleep labo-
ratories with long-lasting expertise in narcolepsy following
virtually identical diagnostic criteria, several procedures vary
between laboratories, and complete and uniform data could
not be obtained from all patients included, introducing some
diagnostic site effects (a structured prospective database has
been launched by the EU-NN in 2010). Some of the
parameters analysed in the study (e.g. onset of EDS) were
based on the reliance on subjects of correctly recalling
symptoms, or in the analysis of retrospective data obtained
from medical charts, which may vary according to differences
in interpretation or in conducting clinical interviews between
sites. We did not compare our patients with a reference
population. Comparisons with subjects recruited from the
same populations and diagnosed either with other hyper-
somnias or without any sleep disorder could have allowed
identification of the most specific (in terms of specificity and
sensitivity) narcolepsy phenotypes and comparisons of
co-morbidities or the search for environmental risks factors
implicated in the pathophysiology of the disease.
In conclusion, this study provides a detailed description of
the clinical and PSG characteristics of a large and homoge-
neous group of patients with NC. Despite major advances
during recent years in our understanding of the neurobiolog-
ical basis of narcolepsy, NC is still an under-recognized
condition. A better knowledge of the nosology of NC may
allow earlier diagnosis of this life-long disabling condition.
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